Evaluating the Addition of Bevacizumab to Endocrine Therapy as first-line treatment for Hormone-receptor positive metastatic breast cancer: A Pooled-analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
- Citation:
- Eur. J. Cancer vol 117 91-98
- Year:
- 2019
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 8
- Parents:
- 2679
- Children:
- None
- Pharmas:
- Genentech, Roche
- Grants:
- U10CA180821, U10CA180882, P30 CA008748, U10CA180838, U10CA180867
- Corr. Author:
- Authors:
- M. Martín S. Loibl T. Hyslop J. De la Haba-Rodríguez B. Aktas C. T. Cirrincione K. Mehta W. T. Barry S. Morales L. A. Carey J. A. Garcia-Saenz A. Partridge N. Martinez-Jañez O. Hahn E. Winer A. Guerrero-Zotano C. Hudis M. Casas C. Rodriguez-Martin J. Furlanetto E. Carrasco M. N. Dickler
- Networks:
- LAPS-CT018, LAPS-IL057, LAPS-MA036, LAPS-NC007, LAPS-NY016
- Study
- CALGB-40503
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- advanced breast cancer, endocrine therapy, bevacizumab, pooled-analysis